Keeping Current CME
Evolving Treatment Landscape for mHSPC: Latest Clinical Data and Implications for Practice
November 26, 2024
Did you know androgen deprivation monotherapy is no longer considered standard of care for metastatic hormone-sensitive prostate cancer (mHSPC) by experts? Credit available for this activity expires:
Hear from experts as they discuss timely clinical topics as well as relevant and actionable strategies for practice improvement. This podcast is available for CME credit.
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!